Vialox vs MK-677 (Ibutamoren)
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
VialoxGrowth Hormone Peptides
MK-677 (Ibutamoren)- Summary
- Vialox is a synthetic pentapeptide that mimics the activity of conotoxin from cone snails, acting as an antagonist of nicotinic acetylcholine receptors at the neuromuscular junction. Similar to Syn-Ake but derived from cone snail venom biochemistry, it reduces facial muscle contraction to smooth expression wrinkles.
- MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
- Half-Life
- Not applicable (topical; effect duration hours)
- 24 hours
- Admin Route
- Topical
- Oral
- Research
- —
- —
- Typical Dose
- 0.005-0.05% in formulation
- 10–25 mg
- Frequency
- Twice daily
- Once daily
- Key Benefits
- Reduces dynamic wrinkles from repetitive facial expressions
- Reversible muscle-relaxing effect without injection
- Smooths forehead, periorbital, and perioral lines
- Complementary to collagen-stimulating peptides
- Well-studied tolerability in cosmetic concentrations
- Can be combined with Syn-Ake for dual conotoxin/viper venom effect
- Increases lean muscle mass
- Enhances bone density
- Improves sleep quality and REM sleep
- Accelerates recovery from training
- Increases appetite
- May improve skin elasticity and appearance
- Supports fat loss while maintaining muscle
- Oral administration — no injections required
- 24-hour half-life allows once-daily dosing
- Side Effects
- Generally very well-tolerated topically
- Rare contact sensitivity or mild irritation
- No clinically significant systemic neuromuscular effects at cosmetic doses
- Increased appetite (significant in some users)
- Water retention and puffiness
- Elevated blood glucose / insulin resistance (monitor in diabetics)
- Lethargy initially
- +2 more
- Stacks With
- —
- —